Graves' disease is the most common cause of thyrotoxicosis and is characterized by ophthalmopathy with proptosis, chemosis, or conjunctival injection; pretibial myxedema; and thyroid acropachy. It is an autoimmune disease that can be genetic or influenced by coexisting environmental factors such as exposure to anticancer drugs, including immune checkpoint inhibitors. The incidence rate of breast cancer is increasing due to rising awareness of risk factors and screening for breast cancer, and the mortality rate is decreasing due to recent advances in cancer treatment. However, there are side effects that are attributed to these treatment modalities, manifesting in various forms in breast cancer survivors, which are reflected in the patient in this case study.
Get full access to this article
View all access options for this article.
References
1.
SharmaA, StanMN. Thyrotoxicosis: Diagnosis and management. Mayo Clin Proc, 2019; 94(6):1048–1064; doi: 10.1016/j.mayocp.2018.10.011
DobrinjaC, ScomersiS, GiudiciF, et al.Association between benign thyroid disease and breast cancer: A single center experience. BMC Endocr Disord, 2019; 19(1):104; doi: 10.1186/s12902-019-0426-8
4.
RahmanS, ArchanaA, JanAT, et al.Molecular insights into the relationship between autoimmune thyroid diseases and breast cancer: A critical perspective on autoimmunity and ER stress. Front Immunol, 2019; 10:344; doi: 10.3389/fimmu.2019.00344
5.
MullerI, Barrett-LeeP. The antigenic link between thyroid autoimmunity and breast cancer. Semin Cancer Biol, 2020; 64:122–134; doi: 10.1016/j.semcancer.2019.05.013
6.
FierabracciP, PincheraA, CampaniD, et al.Association between breast cancer and autoimmune thyroid disorders: No increase of lymphocytic infiltrates in breast malignant tissues. J Endocrinol Invest, 2006; 29(3):248–251; doi: 10.1007/bf03345548.
7.
SchragaED. Hyperthyroidism, Thyroid Storm, and Graves Disease. Medscape; 2022. Available from: https://emedicine.medscape.com/article/767130-overview [Last accessed: August7, 2022].
8.
LeeSL, AnanthakrishnanS. Hyperthyroidism and Thyrotoxicosis. (Khadori L. ed.) WebMDLLC. Medscape; 2022. Available from: https://emedicine.medscape.com/article/121865-overview [Last accessed: August7, 2022].
9.
RossDS, BurchHB, CooperDS, et al.American Thyroid Association Guidelines for Diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid, 2016; 26(10):1343–1421; doi: 10.1089/thy.2016.0229
10.
VanderpumpMPJ. Epidemiology of Thyroid Disease and Swelling. Oxford Textbook of Endocrinology and Diabetes 3e. Oxford University Press: Oxford; 2021; pp. 375–383; doi: 10.1093/med/9780198870197.003.0045
11.
TingiE, SyedAA, KyriacouA, et al.Benign thyroid disease in pregnancy: A state of the art review. J Clin Transl Endocrinol, 2016; 6:37–49; doi: 10.1016/j.jcte.2016.11.001.
12.
AzeezTA, AdetunjiTA, AdioM. Thyrotoxicosis in Africa: A systematic review and meta-analysis of the clinical presentation. Egypt J Intern Med, 2022; 34(1):57; doi: 10.1186/s43162-022-00145-5
AndersenSL, OlsenJ, CarléA, et al.Hyperthyroidism incidence fluctuates widely in and around pregnancy and is at variance with some other autoimmune diseases: A Danish population-based study. J Clin Endocrinol Metabol, 2015; 100(3):1164–1171; doi: 10.1210/jc.2014-3588
15.
AnderssonM, ZimmermannMB. Influence of iodine deficiency and excess on thyroid function tests. Thyroid Funct Test, 2010; 1446(1):45–69; doi: 10.1007/978-1-4419-1485-9_3.
16.
MurdacaG, GrecoM, BorroM, et al.Hygiene hypothesis and autoimmune diseases: A narrative review of clinical evidences and Mechanisms. Autoimmun Rev, 2021; 20(7):102845; doi: 10.1016/j.autrev.2021.102845
Amit AkirovM. Hyperthyroidism and Thyrotoxicosis: Diagnosis and Management. 2023. Available from: https://www.endocrinologyadvisor.com/home/topics/thyroid/hyperthyroidism-and-thyrotoxicosis-diagnosis-and-management [Last accessed: July9, 2022].
19.
FasanmadeO. The Scope of Cardiac Complications of Thyrotoxicosis in Lagos, Nigeria. 2021. Available from: https://www.academia.edu/es/65129240/The_scope_of_cardiac_complications_of_thyrotoxicosis_in_Lagos_Nigeria [Last accessed: August7, 2022].
20.
OgberaA, KukuS. Epidemiology of thyroid diseases in Africa. Indian J Endocrinol Metabol, 2011; 15(6):82; doi: 10.4103/2230-8210.83331
21.
BaldiniE, LauroA, TripodiD, et al.Thyroid diseases and breast cancer. J Personal Med, 2022; 12(2):156; doi: 10.3390/jpm12020156
22.
TuranE. Relation between thyroid disease and breast cancer. Int J Cancer Clin Res, 2016; 3(2):1052; doi: 10.23937/2378-3419/3/2/1052
23.
HajtmanováE, MuríňP, KinclováI, et al.Thyropathies in women with breast cancer. Clin Oncol, 2012; 25(2):124–129; Slovak. PMID: 22533887.
24.
SmythPPA. The thyroid and breast cancer. Curr Opin Endocrinol Diabetes Obes, 2016; 23(5):389–393; doi:10.1097/med.0000000000000273
25.
BattaA. Breast cancer in association with thyroid disorders. Scholars Int J Biochem, 2019; 02(11):262–267; doi: 10.36348/sijb.2019.v02i11.001
26.
BachL, KostevK, SchiffmannL, et al.Association between thyroid gland diseases and breast cancer: A case-control study. Breast Cancer Res Treatment, 2020; 182(1):207–213; doi: 10.1007/s10549-020-05675-6
27.
JiskraJ, BarkmanovaJ, LimanovaZ, et al.Thyroid autoimmunity occurs more frequently in women with breast cancer compared to women with colorectal cancer and controls but it has no impact on relapse-free and overall survival. Oncol Rep, 2007; 18(6):1603–1611; doi: 10.3892/or.18.6.1603
28.
ValeaA, GhervanCR, MorarAN, et al.Hasimoto s thyroiditis and breast cancer: Coincidence or correlation?. Arch Balkan Med Union, 2016; 51(1):125–128; Available from https://www.researchgate.net/publication/316136009_Hasimoto's_thyroiditis_and_breast_cancer_Coincidence_or_correlation
29.
MarinaD, Rasmussen ÅK, Buch-LarsenK, et al.Influence of the Anti-Oestrogens Tamoxifen and Letrozole on Thyroid Function in Women with Early and Advanced Breast Cancer: A Systematic Review. U.S. National Library of Medicine; 2023. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883413 [Last accessed: August7, 2022].
30.
GeorgeEV, MandapatiJJ, ChandA. Benign breast disorders and their association with thyroid disorders. J Evid Based Med Healthc, 2019; 6(13):1066–1070; doi: 10.18410/jebmh/2019/222
31.
NishiharaE, FukataS, HishinumaA, et al.Prevalence of thyrotropin receptor germline mutations and clinical courses in 89 hyperthyroid patients with diffuse goiter and negative anti-thyrotropin receptor antibodies. Thyroid, 2014; 24(5):789–795; doi: 10.1089/thy.2013.0431
32.
KelkarMG, ThakurB, DerleA, et al.Tumor suppressor protein p53 exerts negative transcriptional regulation on human sodium iodide symporter gene expression in breast cancer. Breast Cancer Res Treat, 2017; 164(3):603–615; doi: 10.1007/s10549-017-4297-2
33.
YeungS-CJ. Graves Disease. (Kahdori R. ed.) Medscape; 2023. Available from: https://emedicine.medscape.com/article/120619-overview [Last accessed: February9, 2023].
34.
StoynovaM. Thyrotropin-receptor antibodies, immunoglobulin E and antinuclear antibodies in patients with graves' disease and graves' orbitopathy. Acta Endocrinol (Bucharest), 2021; 17(2):194–199; doi: 10.4183/aeb.2021.194
35.
LyttonSD, PontoKA, KanitzM, et al.A novel thyroid stimulating immunoglobulin bioassay is a functional indicator of activity and severity of Graves' Orbitopathy. J Clin Endocrinol Metabol, 2010; 95(5):2123–2131; doi: 10.1210/jc.2009-2470
36.
MullerI, GianiC, ZhangL, et al.Does thyroid peroxidase provide an antigenic link between thyroid autoimmunity and breast cancer?. Int J Cancer, 2013; 134(7):1706–1714; doi: 10.1002/ijc.28493
37.
QasimMK, TektookNK. Relationship of breast cancer association with thyroid disorders in IRAQI women patients. J Nat Remedies, 2020; 21(6):46–52; Available from: https://www.researchgate.net/profile/Nihad-Tektook-2/publication/345035391_RELATIONSHIP_OF_BREAST_CANCER_ASSOCIATION_WITH_THYROID_DISORDERS_IN_IRAQI_WOMEN_PATIENTS/links/5fa82c01a6fdcc
38.
RaveraS, Reyna-NeyraA, FerrandinoG, et al.The sodium/iodide symporter (NIS): Molecular physiology and preclinical and clinical applications. Ann Rev Physiol, 2017; 79(1):261–289; doi:10.1146/annurev-physiol-022516-034125
39.
FarahatiJ, RoggenbuckD, GilmanE, et al.Anti-thyroid peroxidase antibodies are associated with the absence of distant metastases in patients with newly diagnosed breast cancer. Clin Chem Lab Med, 2012; 50(4):709–714; doi: 10.1515/cclm.2011.819.
40.
MullerI, KilburnLS, TaylorPN, et al.TPOAb and thyroid function are not associated with breast cancer outcome: Evidence from a large-scale study using data from the taxotere as adjuvant chemotherapy trial (tact, CRUK01/001). Eur Thyroid J, 2017; 6(4):197–207; doi: 10.1159/000460246
RazekA, El-HadidyEM, MoawadME-S, et al.Assessment of lacrimal glands in thyroid eye disease with diffusion-weighted magnetic resonance imaging. Polish J Radiol, 2019; 84:142–146; doi: 10.5114/pjr.2019.84096
43.
PenmanAD, CrowderKW, WatkinsWM. A Clinical Activity Score that discriminates between inflammatory and noninflammatory graves' ophthalmopathy. In: 50 Studies Every Ophthalmologist Should Know. 2020; 279–284; doi: 10.1093/med/9780190050726.003.0046.
44.
SotoJF, SerranoAM, JiménezDL et al. Transitory hypothyroidism induced by tamoxifen. Rev Clin Espanola, 2014; 214:427–428; Available from: http://doi.org/10.1016/j.rce.2014.05.025 [Spanish; summarised from a translation] Cited on September 5, 2022.
45.
TunioM, Al AsiriM, BayoumiY, et al.Is thyroid gland an organ at risk in breast cancer patients treated with locoregional radiotherapy? Results of a pilot study. J Cancer Res Ther, 2015; 11(4):684; doi: 10.4103/0973-1482.167613
46.
De GrootS, JanssenLGM, CharehbiliA, et al.Thyroid Function Alters During Neoadjuvant Chemotherapy in Breast Cancer Patients: Results from the NEOZOTAC Trial (Boog 2010–01). U.S. National Library of Medicine-Breast Cancer Research and Treatment;, 2015; Vol. 149; pp. 461–466; Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4308642 [Last accessed: August 14, 2022].
47.
FreitasPA, VissociGM, PintoRM, et al.Study of the prevalence of autoimmune thyroid disease in women with breast cancer. Endocr Pract, 2016; 22(1):16–21; doi: 10.4158/ep14445.or
48.
LadarolaC, CroceL, QuaquariniE, et al.Nivolumab induced thyroid dysfunction: Unusual clinical presentation and challenging diagnosis. Front Endocrinol, 2019; 9:813; doi: 10.3389/fendo.2018.00813
49.
AlqaisiS, RahmanA. A rare case of pembrolizumab-associated graves' disease. Cureus, 2023; 15(2):e34696; doi: 10.7759/cureus.34696
50.
Bou-DarghamMJ, DraughonS, CantrellV, et al.Advancements in human breast cancer targeted therapy and immunotherapy. J Cancer, 2021; 12(23):6949–6963; doi: 10.7150/jca.64205
51.
HanselTT, KropshoferH, SingerT, et al.The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov, 2010; 9(4):325–338; doi: 10.1038/nrd3003
52.
MinHK, KimI-H, KimJY, et al.Trastuzumab-associated autoimmune thyroid disease in a patient with metastatic breast cancer. Korean J Intern Med, 2016; 31(3):608–611; doi: 10.3904/kjim.2014.031
GraniG; DicoratoP; DainelliM; et al.Thyroid Diseases in Women with Breast Cancer. U.S. National Library of Medicine. Available from: https://pubmed.ncbi.nlm.nih.gov/23306753 [Last accessed: August15, 2022]
55.
EslavaM, Sánchez-BayonaR, Garcia del BarrioM, et al.Trastuzumab and thyroid dysfunction: An association to be aware of. J Cancer Res Ther, 2022; 18(4):1183; doi: 10.4103/jcrt.jcrt_66_19
